Figure 3. OS (A) and PFS (B) of patients with nontransformed follicular lymphoma treated either with HD-RIT using 131I-tositumomab and ASCT or C-HDT and ASCT.
Figure 3.

OS (A) and PFS (B) of patients with nontransformed follicular lymphoma treated either with HD-RIT using 131I-tositumomab and ASCT or C-HDT and ASCT.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal